Dakota Dunes, S.D.-based Center for Neurosciences, Orthopaedics & Spine physicians have used platelet rich plasma injections to treat more than 100 joint pain patients, according to KTIV News.
Biologics
The Japanese Pharmaceuticals and Medical Devices Agency granted DiscGenics approval for a clinical trial notification application for its IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease.
Kuros Biosciences received FDA 510(k) clearance to extend its MagnetOs Putty indications to use as a standalone bone graft in the extremities and pelvis.
Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.
Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.
Advertisement
The global spinal biologics market is predicted to grow at a 3.75 percent compound annual growth rate, reaching $2.36 billion by 2021, according to a Research Cosmos report.
Anika Therapeutics resumed distribution of its solid hyaluronic acid-based treatments after a voluntary, non-safety related recall in the second quarter.
AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company's fresh cryopreserved osteochondral allograft.
Bio2 Technologies is an orthobiologics company.
The global spine biologics market is projected to grow at a 3.5 percent compound annual growth rate to reach $2.72 billion by the end of 2025, according to a Market Reports World report.